Hepatic arterial chemotherapy (HAC) with oxaliplatin (OXA), leucovorin (LV) and 5-fluorouracil (5FU): A feasible and effective regimen.

被引：0
|
作者：
Del Freo, DFAA
Lombardi, M
Mambrini, A
Muttini, MP
Pennucci, MC
Sanguinetti, F
Torri, T
Cantore, M
机构：
[1] ASL 01 Massa Carrara, Dept Oncol, Carrara, Italy
[2] ASL 01 Massa Carrara, Dept Surg, Carrara, Italy
[3] ASL Massa Carrara, Dept Oncol, Carrara, Italy
[4] ASL 01 Massa Carrara, Dept Radiol, Carrara, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I study of oxaliplatin (OXA), 5-fluorouracil (5FU) and concomitant preoperative irradiation in patients with locally advanced rectal cancer.
    Balart, J
    Marcuello, E
    Garriga, J
    Pernas, J
    Sancho, F
    González, D
    Pétriz, L
    Llaurado, J
    Martínez, A
    Guallar, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 304S - 304S
  • [42] Hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma
    Melichar, B.
    Ferko, A.
    Krajina, A.
    Rouskova, L.
    Dvorak, J.
    Svebisova, H.
    Neoral, C.
    Koecher, M.
    Malirova, E.
    Paral, J.
    JOURNAL OF BUON, 2012, 17 (04): : 677 - 683
  • [43] Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin
    Codacci-Pisanelli, G.
    Noordhuis, P.
    van der Wilt, C. L.
    Peters, G. J.
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2008, 27 (6-7): : 733 - 739
  • [44] Oxaliplatin (OXA)/5-fluorouracil (5FU)/folinic acid (FA) in patients (pts) with advanced colorectal cancer (ACRC): Report of an Algerian trial
    Oukkal, M
    Mahfouf, H
    Larbaoui, B
    Djellali, L
    Smail, N
    Benhabyles, B
    Rebaine, M
    Makhloufi, A
    Benouniche, N
    Bouzid, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 304S - 304S
  • [45] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [46] Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC)
    Goldstein, Daniel A.
    Chen, Qiushi
    Howard, David H.
    Lipscomb, Joseph
    Ayer, Turgay
    Harvey, Donald
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Toxicity profile following adjuvant therapy using CPT-11, 5-fluorouracil (5FU) and leucovorin (LV) in patients with rectal cancer.
    Kalofonos, HP
    Kardamakis, D
    Bamias, A
    Papakostas, P
    Timotheadou, E
    Samelis, G
    Xiros, N
    Pavlidis, N
    Skarlos, D
    Fountzilas, G
    ANNALS OF ONCOLOGY, 2000, 11 : 46 - 47
  • [48] Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.
    Flejou, Jean-Francois
    Andre, Thierry
    Chibaudel, Benoist
    Scriva, Aurelie
    Hickish, Tamas
    Tabernero, Josep
    Van Laethem, Jean-Luc
    Banzi, Maria
    Maartense, Eduard
    Shani, Adi
    Carlsson, Goeran
    Scheithauer, Werner
    Papamichael, Demetris
    Moehler, Markus
    Landolfi, Stefania
    Demetter, Pieter
    Duval, Alex
    Lee, Mark
    Colote, Soudhir
    De Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Phase III trial of 5-fluorouracil (5FU) and leucovorin (LV) with or without trimetrexate (TMTX) as first line treatment in advanced colorectal cancer(ACC)
    Punt, CJA
    Keizer, HJ
    Douma, J
    Schüller, J
    Skovsgaard, T
    ten Napel, CHH
    Lochs, H
    Muller, EW
    Russell, L
    Wagener, DJT
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S68 - S68
  • [50] A phase II study in patients with advanced biliary tract carcinoma (BTC) treated with hepatic arterial infusion chemotherapy (HAI) with oxaliplatin (O), 5-fluorouracil (5FU), and folinic acid (FA).
    Nicolaou, A.
    Sinn, M.
    Hildebrandt, B.
    Gebauer, B.
    Ricke, J.
    Doerken, B.
    Riess, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345